What Is The Status Of The Latisse For Hair Loss Study?

May 18th, 2011

Q: I saw your post on the clinical trials of Latisse (bimatoprost) for hair loss on the scalp. What is the status of the study? — B.V., New Providence, NJ

A: Allergan, the company that makes Latisse, is conducting safety and efficacy testing of three formulations of the drug for men with androgenetic alopecia (male pattern baldness).

The first phase of the trials is now complete and the study has moved into phase II. In this phase, the pharmaceutical company will be studying the results of the same three formulations of the drug, but this time they will be comparing them to results of a control option and also an over-the-counter minoxidil 5% solution.

This study is scheduled to begin in June 2011 and end in September 2011. It is important to note that bimatoprost is not yet FDA approved for the treatment of scalp hair loss.

For more information, view the details of the study on ClinicalTrials.gov.

Read more about Latisse/Bimatoprost.

Related Posts:

Rating:  1 Star2 Stars3 Stars4 Stars5 Stars  


Tags:  , , , , , , , ,
Posted by Robert M. Bernstein M.D. on May 18th, 2011 at 6:10 pm

Browse Hair Restoration Answers by topic:

© 2005-2016 Bernstein Medical, P.C. All Rights Reserved.

ARTAS, ARTAS Hair Studio, and RESTORATION ROBOTICS logo are among the trademarks and/or registered trademarks of Restoration Robotics, Inc. in the United States and/or other countries.